SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
Instant Clinical Pharmacology E.J. Begg
First, zero, pseudo-zero order elimination Clearance
PHARMACOKINETIC.
The half-life OCT 2010.
Non compartmental analysis
PHYSIOLOGIC PHARMACOKINETIC MODEL
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Selected bioavailability and pharmacokinetic calculations Dr. Osama A. A. Ahmed.
Pharmacokinetics of Drug Absorption
Nonlinear pharmacokinetics
Two-compartment model
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
One-compartment open model: Intravenous bolus administration
Exercise 6 Dose linearity and dose proportionality
Week 3 - Biopharmaceutics and Pharmacokinetics
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Week 4 - Biopharmaceutics and Pharmacokinetics
Toxicokinetic Calculations
Gokaraju Rangaraju College of Pharmacy
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
INTRAVENOUS INFUSION.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
University of Jordan-Faculty of Pharmacy
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Principles of Clinical Pharmacology Noncompartmental versus Compartmental Approaches to Pharmacokinetic Data Analysis David Foster, Professor Emeritus.
Pharmacokinetics Introduction
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
PHARMACOKINETIC MODELS
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
Pharmacokinetics of Drug Absorption Prepared by: KAZI RASHIDUL AZAM.
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Intravenous Infusion Previous rates of administration were instantaneous IV bolus and first order absorption. As a rate (mg/hr) a first order rate constantly.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.
Continuous intravenous infusion (one-compartment model)
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Phoenix WinNonLin Assignment Due Today Access Phoenix remotely.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Lecture 2 Clearance, maintenance dose and AUC
PHT 415 BASIC PHARMACOKINETICS
The General Concepts of Pharmacokinetics and Pharmacodynamics
Pharmacokinetics 3rd Lecture
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
Allie punke Pharmacokinetics tutoring Fall 2016
Physiology for Engineers
Allie punke Pharmacokinetics tutoring Fall 2016
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Chapter 7 COMPARTMENT MODELS
Lecture-8 Biopharmaceutics
CONCEPT OF PHARMACOKINETICS- ONE COMPARTMENT MODEL
Applications of Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Lab-3 practical pharmacology
Quantitative Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
NONCOMPARTMENTAL ANALYSIS
Hawler Medical University
Therapeutic Drug Monitoring chapter 1 part 1
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS Presented by: Ch. Karthik Siva Chaitanya M.Pharm (1st sem),Pharmaceutics UCPSc,KU.

Contents: Introduction to noncompartmental pharmacokinetic approach Differences between compartment and noncompartment models Concepts of noncompartmental model Statistical moments theory-Mean residence time Different pharmacokinetic parameters in noncompartment model Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Based on the statistical moment theory. Model independent method Noncompartment pharmacokinetics is a new approach devised to study the time course of drug in the body with out assuming any compartment model. Based on the statistical moment theory. Model independent method Overcomes some of the drawbacks associated with classical compartment modeling. Basic assumption is that drug or metabolite follows first-order kinetics. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Noncompartment and Compartment models – Comparison Noncompartment models These require elaborate assumptions to fit the data Do not require assumptions to compartment model. Curve fitting of experimental data using computers. It is a tedious method. Simple algebraic equations. No curve fitting and no computers Applicable to linear and nonlinear pharmacokinetics Applicable to linear pharmacokinetics. C1 - time profile is regarded as expressions of exponents C1 – time profile is regarded as statistical distribution. These are useful for most of the situations, though assumptions of modeling are involved. Particularly useful for the applications of clinical pharmacokinetics, bioavailability, and bioequivalence studies. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Advantages: Derivation of PK parameters is easy, because of simple algebraic equations Mathematical treatment remains same, for drug or metabolite, provided elimination follows first order kinetics Drug disposition kinetics need not be described in detail Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Disadvantages: Information regarding plasma drug concentration-time profile is expressed as an average Generally not useful for describing the time course of drug in the blood It is applicable only for linear pharmacokinetics Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Statistical Moment Theory Statistical moment: A mathematical description of a discrete distribution of data. Statistical moments calculated from a set of concentration-time data represent an estimate of the true moment (or the true probability density function (PDF)that describes the true relationship between concentration and time). Statistical moment theory provides a unique way to study time-related changes in macroscopic events. Assume the drug molecules are eliminated according to a kinetic function, f(t) = C 0e – kt Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Eq.1 2 [AUC]0 =  C dt 1 3 [AUMC]0 =  t x C. dt Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

I.V. bolus injection – Calculation of AUC and AUMC Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Mean residence time(MRT): The term mean residence time (MRT) describes the average time for all the drug molecules to reside in the body. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

MRT represents the time for 63. 2% of drug eliminated when given i. v MRT represents the time for 63.2% of drug eliminated when given i.v. bolus injection. It is analogous to plasma elimination half life, t1/2, i.e., 50% elimination. Like half life, MRT is a function of both distribution and elimination For i.v bolus dose Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Plasma elimination half life : t1/2 = k10 In noncompartmental terms, k is constant equal to ratio of clearance to Vss Vss is volume of distribution at steady state t1/2 = 0.693MRT MRTiv is used for comparison. For eg: following constant rate of infusion Where T = duration of infusion 0.693 Plasma elimination half life : t1/2 = k10 Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

DRUG ABSORPTION: MAT(Mean absorption time) is defined as the differences in mean residence time (MRT) after different modesof administration. MAT = MRTni – MRTiv MRTni = mean residence time of drug by non- instantaneous route, h MRTiv = mean residence time of drug by i.v. bolus injection Same equation is used for i.m. injection Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

When absorption follows zero order T = time over which absorption takes place, h MAT can be used for comparision of dosage forms Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

OTHER APPLICATIONS OF MRT Mean Dissolution Time(MDT) MDT=MRTtest-MRTsoln In oral administration, MRToral=MRTiv+1/Ka For evaluation of absorption data, MAT=MRTtest-MRTiv MAT=1/Ka Ka is first order absorption rate constant Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Drug Clearance: After iv bolus administration, At steady state after constant rate iv infusion Ko is rate of infusion ; Css is steady state concentration By using extraction ratio Cl=Q(ER) Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

APPARENTVOLUME OF DISTRIBUTION: Vss is volume of distribution at steady state independent of elimination Vss =i.v dose(AUMC)/(AUC) If drug is given by constant rate i.v infusion Where Ko is infusion rate; is duration of infusion Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Steady State Plasma Drug Concentration: The Css is a function of the effective rateof dosing and total body clearance of thedrug in a patient Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

F is fraction bioavailable AUCss is AUC from t=0 to t= during a dosinginterval at steady state F is fraction bioavailable Method of superposition is used for predicting steady state concentration on repetitive dosing from data obtained after a single dose. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Predicting the Time to Steady State: Time required for the drug to reach steady state, i.e., 99%, takes 6.65 half lives. In extravascular route (or prolongedrelease drug products), the time requiredto attain ss takes longer than predicted bybiological half life In multicompartment disposition, timerequired to attain to ss is shorter than that predicted by terminal half life Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

AUC = area under the curve in single dose In noncompartmentmodels, when the drug isadministered repetitive dosing, fss AUC = area under the curve in single dose Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Bioavailability: Bioavailability refers to the fractional dose of a dosage form reaches systemic circulation. For i.v. bolus injection, bioavailability is referred as unity (=1) Bioavailability (F) of a dosage form Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

Fraction metabolised: AUCx1 Fraction metabolized, Fm = AUC1 AUCx1 is area under the curve of metabolite concentrationin plasma versus time from zero to infinity AUC1 is the total area under the metabolite concentration –time curve after a equimolar intravenous dose of a metabolite Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU 23

CONCLUSION: The noncompartmental pharmacokinetic methods permit a comprehensive pharmacokinetic analysis with out resort to curve fitting,sophisticated computers or tedious mathematical equations. Although these methods cannot be applied to all pharmacokinetic problems,they are useful for most problems and are particularly useful for the clinical application of pharmacokinetics. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

References: Milo Gibaldi , Biopharmaceutics and clinical pharmacokinetics, 4th edition ,pg no 17-26 D.Perrier,M.Gibaldi Pharmacokinetics, 2nd edition , pg no 409-417 Leon Shargel ,Applied biopharmaceutics and pharmacokinetics,5th edition,pg no 717-753 V.Venkateshwarlu,Biopharmaceutics and pharmacokinetics, pg no 309-330 www.pharainfo.net Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU

THANK YOU Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU